Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- CANTA.ST
- Price
- 1.30
- Stock movement down
- -0.01 (-1.07%)
- Company name
- Cantargia AB
- Exchange
- (ST ,
- Currency
- SEK )
- Sector
- Healthcare >Biotechnology
- Market cap
- 238.79M
- Ent value
- 209.07M
- Price/Sales
- -
- Price/Book
- 4.88
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- 7.55%
- 1 year return
- -71.43%
- 3 year return
- -55.93%
- 5 year return
- -37.59%
- 10 year return
- -16.85%
Last updated: 2025-04-12
DIVIDENDS
CANTA.ST does not pay dividends or no data was received
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | - |
| Price to Book | 4.88 |
| EV to Sales | - |
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 183.69M |
| EPS (TTM) | -1.05 |
| FCF per share (TTM) | -1.05 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 0.00 |
| Gross profit (TTM) | -2.59M |
| Operating income (TTM) | -199.00M |
| Net income (TTM) | -193.53M |
| EPS (TTM) | -1.05 |
| EPS (1y forward) | -0.94 |
Margins
Loading...
Margins data
| Gross margin (TTM) | - |
| Operating margin (TTM) | - |
| Profit margin (TTM) | - |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 59.81M |
| Net receivables | 0.00 |
| Total current assets | 72.11M |
| Goodwill | 0.00 |
| Intangible assets | 3.98M |
| Property, plant and equipment | 0.00 |
| Total assets | 79.02M |
| Accounts payable | 5.70M |
| Short/Current long term debt | 0.00 |
| Total current liabilities | 29.89M |
| Total liabilities | 30.09M |
| Shareholder's equity | 48.94M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -192.99M |
| Capital expenditures (TTM) | 0.00 |
| Free cash flow (TTM) | -192.99M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -395.46% |
| Return on Assets | -244.90% |
| Return on Invested Capital | -395.46% |
| Cash Return on Invested Capital | -394.35% |
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 1.32 |
| Daily high | 1.35 |
| Daily low | 1.28 |
| Daily Volume | 182K |
| All-time high | 58.00 |
| 1y analyst estimate | 9.70 |
| Beta | 1.74 |
| EPS (TTM) | -1.05 |
| Dividend per share | - |
| Ex-div date | - |
| Next earnings date | 13 May 2025 |
Downside potential
Loading...
Downside potential data
| CANTA.ST | S&P500 | |
| Current price drop from All-time high | -97.76% | -12.89% |
| Highest price drop | -97.85% | -56.47% |
| Date of highest drop | 7 Apr 2025 | 9 Mar 2009 |
| Avg drop from high | -54.75% | -11.07% |
| Avg time to new high | 50 days | 12 days |
| Max time to new high | 1102 days | 1805 days |
COMPANY DETAILS
Marketcap
238.79M
Marketcap category
Small-cap
Description
Cantargia AB (publ), a biotechnology company, develops antibody-based treatments for life threatening diseases. The company is developing CAN04 (nadunolimab), an interleukin-1 receptor accessory protein (IL1RAP) binding antibody, which is in Phase II clinical trial for the treatment of pancreatic cancer, non-small cell lung cancer, and triple-negative breast cancer; and CAN10, an antibody against IL1RAP, which is in preclinical phase for the treatment of autoimmune and inflammatory diseases, including systemic sclerosis and myocarditis. It also develops CANxx, an IL1RAP-based antibody platform. The company has collaboration agreements with Patheon Biologics B.V. and BioWa Inc. for the manufacture and production of CAN04; and GEICAM, Spanish breast cancer group. Cantargia AB (publ) was incorporated in 2009 and is based in Lund, Sweden.
Employees
23
Website
Investor relations
-
SEC filings
CEO
Country
Sweden
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
All newsPress releases
LUND, SE / ACCESS Newswire / April 11, 2025 / Cantargia (STO:CANTA) - Cantargia (Cantargia AB (publ); Nasdaq Stockholm:CANTA) today announced that the annual report for 2024 has been published. The An...
April 11, 2025
LUND, SE / ACCESS Newswire / April 11, 2025 / Cantargia (STO:CANTA) - The shareholders of Cantargia AB (publ) are invited to the annual general meeting on Thursday, 15 May 2025, at 15.00 CEST at Ideon...
April 11, 2025
LUNDE, SE / ACCESS Newswire / April 1, 2025 / Cantargia (STO:CANTA) - Cantargia AB (publ) ("Cantargia") (Nasdaq Stockholm:CANTA) today announced the appointment of Morten Lind Jensen, MD, PhD, as Chie...
April 1, 2025
LUND, SWEDEN / ACCESS Newswire / March 25, 2025 / Cantargia (STO:CANTA) Nadunolimab's additional potential in mitigating neuropathy demonstrated by data from Cantargia's CESTAFOUR and CAPAFOUR clinica...
March 25, 2025
LUND, SE / ACCESS Newswire / March 25, 2025 /Cantargia (STO:CANTA) Cantargia (Cantargia AB (publ); Nasdaq Stockholm:CANTA) today announced an upcoming presentation of preclinical data on the developme...
March 25, 2025
LUND, SE / ACCESS Newswire / March 13, 2025 / Cantargia (STO:CANTA) Cantargia AB (publ) ("Cantargia") (Nasdaq Stockholm: CANTA) today announced that members of Cantargia's management will participate ...
March 13, 2025
LUND, SE / ACCESS Newswire / March 12, 2025 / Cantargia (STO:CANTA) Open label study in forty AML and MDS patients Study financed by the US Department of Defense Cantargia (Cantargia AB; Nasdaq Stockh...
March 12, 2025
TRIFOUR is Cantargia's first randomized, controlled study of nadunolimab First preliminary efficacy results expected mid-2025 LUND, SWEDEN / ACCESS Newswire / March 10, 2025 / Cantargia (Cantargia AB)...
March 10, 2025
LUND, SE / ACCESS Newswire / March 6, 2025 /Cantargia (STO:CANTA) Cantargia AB (publ) ("Cantargia") (Nasdaq Stockholm: CANTA) today announced that Damian Marron, Interim CEO, will participate at the H...
March 6, 2025
LUND, SE / ACCESS Newswire / March 5, 2025 / Cantargia (STO:CANTA) Promising multiple dose PK data continue to support 4-weekly dosing FDA advice received supporting phase 2 design in HS Strong Key Op...
March 5, 2025
Next page